Introduction

20
Adoption of regenerative medicine (RM) therapies is relatively unchartered territory, with 21 few approved demonstrators having secured reimbursement. In ophthalmology there are a 22 variety of indications in which RM and more specifically cell therapy would offer very real 23 benefit [1, 2] . However, for these benefits to be realised, therapy developers must 24 Regenerative Medicine understand the drivers and potential determinants of uptake into healthcare. This will be 25 critical to the development of the industry sector and core both to affording widespread 26 patient access to these therapies, and in realising national economic benefit from attracting 27 industry investment [3] . 28 Healthcare markets around the world vary significantly in the way that healthcare is 29 financed and delivered. Both the UK's National Health Service (NHS) and Canada's Medicare 30 are well appreciated examples of "single-payer" healthcare systems in which healthcare is 31 funded through taxation, and delivered through publicly governed providers [4] . The NHS 32 has been characterised as a slow adopter of medical technologies, described to be behind 33 many other countries in terms of the therapies it provides [5] [6] [7] . 34 To understand if the market characteristics of the NHS are a consequence of its operation as 35 a single-payer system, this work has attempted to draw comparisons with Canada. Canada 36 has received more attention in recent years for its long waiting lists for elective surgeries 37 and high prices paid for patented pharmaceuticals [8, 9] . Both the UK and Canada are world 38 leaders in the basic research of RM, with both countries' governments keen to gain 39 economic benefit from commercially exploiting this exciting area of technology [10, 11] 40 Ophthalmology has been a target area of particular interest to therapy developers for 41 several reasons. The eye is a small, enclosed, largely immune-privileged organ, which allows 42 relatively easy surgical access [12, 13] . Transplant sites can be easily visualized on account of 
Methods
57
This study used a qualitative design based on "problem-centered interviews" (PCI) [19] . The 58 data collection phase ran from Jan 2013 to Sept 2013. 22 consultant ophthalmologists with 59 links to RM research programmes were contacted in both the UK and Canada. Respondents 60 were interviewed face-to-face and in cases when this was not possible by telephone. 34 61 candidates were invited for interview in the UK. 44 candidates were invited in Canada to 62 reach an equal number of participants in both territories (11 participants). 
Data Collection 64
An interview framework was developed using results from an unpublished literature review 65 conducted at the start of this work. regions. As might be expected there were differences in the responses given across the 98 sample which appeared to be predicated on the types of institutions within which these 99 ophthalmologists practiced. In general, respondents working for high profile research 100 centres appeared to look favourably on the systems and processes which supported the 101 adoption of new therapies. On the other hand, clinicians coming from smaller centres gave 102 evidence that they were frustrated with the pace of change, the bureaucracy and the 103 amount of justification required to adopt a therapy, which had been used effectively the UK and Canada collectively in the PCI, importantly four of these in the UK (Table 2) . healthcare system is autonomous and sets its own healthcare priorities. As a consequence, 324 system-level reimbursement and even technology appraisals will largely be done at a sub-325 national level in Canada. 326 Large variations in the way healthcare adoption was managed and implemented appeared 327 to be a theme on which both UK and Canadian participants agreed. Whilst such 328 fragmentation may be expected from the Canadian system, made up of independent 329 provincial ministries governing healthcare, the fragmentation and regional and local 330 differences in operations in the NHS was perhaps less expected. 331 The regional management variations in healthcare were identified by 7 UK participants, 332 underlining the complex and heterogeneous system of healthcare in the NHS. Currently, the One UK ophthalmologist recognised that RM therapies for rarer diseases may be unsuitable 398 for NICE appraisal and may well be better serviced by specialised services commissioning. (Table 4) , the systems have developed significantly different 420 processes for dealing with the uptake of RM therapies (Table 5) . Whilst both offer some 421 form of evidence-based healthcare, the two are still guided by value for money, and 422 differences in the way that value for money is assessed between the two nations (Table 3) 423 will be an important area for future exploration. 
Conclusions
455
The aim of this work was to identify the factors likely to determine adoption of RM therapies in 456 ophthalmology in the UK and Canada. Factors which appeared to be similar between the UK and the 457 comparator, Canada included evidence-based decision making; bureaucracy, and regional 458 management issues. However there were several differences that emerged from the samples that 459 will no doubt impact on adoption of future RM therapies. 460
Favourable processes surrounding clinical research infrastructure, funding and ethics approval 461 appear to have contributed to making the UK a more favourable setup than Canada for RM 462 translation in ophthalmology in recent years. However when it comes to early use and system-wide 463 adoption of RM therapies, the NHS was perceived to find uptake harder to manage, with local 464 management and institutional infrastructure being perceived far more of a barrier than in Canada. 465
Examples of excellent management behaviours and setup in Canadian ophthalmology departments 466
were an area which NHS management would do well to learn from. Several participants giving 467 examples of forward thinking and innovative programmes to drive adoption and ensure Canadian 468 clinicians bridged the gap between translation and adoption of such therapies. 469
Each healthcare system is associated with national assets which could be appealing to therapy 470 developers working in this space. Health Canada has in recent years proven itself to be a forward 471 thinking regulator willing to look at RM therapies as exceptional technologies. In addition local 472 healthcare providers appeared more supportive of earlier use of therapies and isolated cases uptake 473 of RM into clinical programs. Internally in the UK, the investment and growth of Moorfields Eye 474
Hospital whilst seen by some UK insiders as a sink for UK funding in ophthalmology, has undoubtedly 475 given the UK a competitive advantage in basic and clinical research in RM. 476
As markets, single-payer healthcare systems do have some similar characteristics (Box 1) and they 477 could have the potential to offer a "one-stop shop" for therapy developers to tackle. Ideologically, a 478 single value system, with a uniform willingness to pay, is a far simpler proposition than that of the 479 numerous evaluation procedures in insurance based healthcare systems. Arguably the biggest 480 challenge in building a sustainable RM industry sector in both the UK and Canada will be in 481 persuading decision makers to adopt truly innovative therapies which in the short term may not be 482 cost effective, but that could give rise to a range of therapeutics which change the way we deliver 
Executive Summary
497
Translation 498
• The UK appears to offer a favourable environment for translation of RM therapies, providing 499 a supportive environment through investment into infrastructure. 500
• The Canadian research ethics process is currently a rate limiting component of the clinical 501 trial process 502
Early Use 503
• Canadian regulators Health Canada have demonstrated a desire to move RM forward, being 504 first to approve a number of RM therapies. 505
• Healthcare provider management in Canada appears to be driving innovation and adoption 506 of new ways of working. 507
• The NHS's specialist commissioning group are developing new routes for adoption of 508 therapies targeting low patient numbers (CtE), likely to be relevant for RM therapies. 509 510
System-Wide Adoption 511
• The NHS is still recognised as unresponsive, and has been slow to uptake new medicines, 512 especially struggling with disruptive innovations. 513
• Short term commissioning behaviours and silo budgets in the NHS could make it challenging 514 to demonstrate to decision makers the real value of potentially "curative" treatments. 515
• NICE is internationally recognised as a leader in clinical guidance and technology 516 assessment. Canada's multiple technology assessment processes are less coordinated and 517 significantly more complex to navigate. 518 519
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